Influenza Vaccination Update Letter

CDC Update: Seasonal Influenza Vaccination

Dear Healthcare Executive,

The Centers for Disease Control and Prevention (CDC) has updated its recommendations for seasonal influenza vaccination to include quadrivalent influenza vaccines1

Today’s trivalent flu vaccines help protect against two A strains, and one B strain. Flu vaccine efficacy is partly dependent on how closely related the viruses in the vaccines are to the flu viruses circulating that year. When the viruses in the vaccine are significantly different from those circulating in the community, it is called a mismatch.2 Indeed, between 2001 and 2012, the B lineage in the influenza vaccine did not match the predominantly circulating B lineage in 6 of the 11 flu seasons.3,4

Adding another B strain to the influenza vaccine to include two A strains and two B strains is a public health measure that may help close the gaps in influenza coverage.

Click to download a letter that may be forwarded to your in-network healthcare providers to inform them about the new CDC influenza vaccination recommendation for children and adults, as well as important information about seasonal influenza virus.

  • The previous information was general information about influenza disease
  • The information that follows is specific to FLUARIX® QUADRIVALENT (Influenza Virus Vaccine)
  • Approval of FLUARIX QUADRIVALENT for use in preventing influenza disease caused by influenza A and influenza B was based on immune response data
  • FLUARIX QUADRIVALENT has not been proven to have a positive impact on the potential consequences or outcomes of influenza A or influenza B
  • To determine whether FLUARIX QUADRIVALENT is right for your patients, please see the accompanying complete Prescribing Information


FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons 3 years of age and older.

Important Safety Information for FLUARIX QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT to anyone with known severe allergic reactions (anaphylaxis) to any component of the vaccine, including egg protein, or a life-threatening reaction to previous administration of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • The tip caps of the prefilled syringes may contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals
  • If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • In clinical trials with FLUARIX QUADRIVALENT, the most common adverse reactions in adults were pain at the injection site, muscle aches, headaches, and fatigue. In children 3 through 17 years of age, injection site adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse events were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse events were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients

Click to download the CPT® code to use for FLUARIX QUADRIVALENT intramuscular injection. This one-page document may be forwarded to healthcare providers and used for updating your own records to ensure the code is correctly activated in your plan’s coding and reimbursement system.

Comments are closed.